Overview

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Status:
Completed

Trial end date:
2020-12-07

Target enrollment:

Participant gender:

Summary

The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.

Phase:

Phase 3

Details

Lead Sponsor:

Actelion

Treatments:

Macitentan